Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor

Menopause

Volumn 18, Issue 7, 2011, Pages 821-824

  Dieudonné, Anne Sophie ^a   Vandenberghe, Johan ^a   Geerts, Inge ^b   Billen, Jaak ^b   Paridaens, Robert ^a   Wildiers, Hans ^a   Neven, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Laboratory Medicine   (Belgium)

Author keywords

Antim llerian hormone; Aromatase inhibitor.; Breast cancer; Menopausal state

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GOSERELIN; MUELLERIAN INHIBITING FACTOR; TAMOXIFEN;

ADD ON THERAPY; ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED AMENORRHEA; CHEMOTHERAPY INDUCED OVARIAN FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEMALE FERTILITY; HORMONE DETERMINATION; HUMAN; MENOPAUSE; MULTIPLE CYCLE TREATMENT; OVARY FUNCTION; OVARY INSUFFICIENCY; PREMENOPAUSE; VAGINA BLEEDING;

ADMINISTRATION, ORAL; ADULT; AMENORRHEA; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; FERTILITY; HUMANS; MENOPAUSE, PREMATURE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OVARY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; RECOVERY OF FUNCTION; TAMOXIFEN;

EID: 79959704396     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318204af88     Document Type: Article

References (15)

1. World Health Organization. Research on the Menopause in the 1990s. Technical Report Series 866. Geneva, Switzerland: WHO, 1996.
2. Clemons M, Simmons C. Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat 2007;104:115-120. (Pubitemid 47084222)
3. Hargis JB, Nakajima ST. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest 2006; 24:174-177.
4. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583-2592. (Pubitemid 44542149)
5. Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444-2447. (Pubitemid 46630620)
6. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045-1051. (Pubitemid 46638800)
7. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;7:CD002249. Review.
8. Vandenput I, Vergote I, Amant F, Neven P, Paridaens R, Christiaens MR. Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling. Breast J 2006;12:507-508. (Pubitemid 44337455)
9. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-müllerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-743.
10. van Disseldorp J, Faddy MJ, Themmen APN, et al. Relationship of serum anti-müllerian hormone concentration to age of menopause. J Clin Endocrinol Metab 2008;10:2129-2134. (Pubitemid 351831526)
11. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and anti-müllerian hormone: markers of ovarian response in IVF/ICSI patientsi BJOG 2004;111:1248-1253. (Pubitemid 39472171)
12. Su HI, Sammel MD, Green J, et al. Antimüllerian hormone and inhibin B are hormone measures of ovarian function in late reproductiveYaged breast cancer survivors. Cancer 2009;116:592-599.
13. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Antimüllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-3483.
14. Guerif F, Lemseffer M, Couet ML, Gervereau O, Ract V, Royère D. Serum antimüllerian hormone is not predictive of oocyte quality in vitro fertilization. Ann Endocrinol 2009;70:230-234.
15. Ortmann O, Cufer T, Dixon JM, et al. Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 2009;18:2-7.